Polyphenon E

Drug Profile

Polyphenon E

Alternative Names: Green tea polyphenols; Polyphenon E; Polyphenon E (green tea extract); Polyphenon E Ointment; SB 03; Sinecatechins; Sinecatechins 10% ointment; Sinecatechins 15%; STA-2 - Sinphar Pharmaceutical; Veregen

Latest Information Update: 02 Jun 2016

Price : $50

At a glance

  • Originator Mitsui Norin; Polyphenon Pharma
  • Developer Maastricht University; MediGene AG; Polyphenon Pharma; SynCore Biotechnology; Triton Pharma; Will-Pharma
  • Class Antineoplastics; Antivirals; Catechins; Herbal medicines
  • Mechanism of Action Antioxidants; Immunostimulants; Viral fusion protein inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Genital warts
  • Phase II/III Basal cell cancer
  • Phase II Prostatic intraepithelial neoplasia
  • Preclinical Bladder cancer
  • Discontinued Actinic keratosis; Angina pectoris; Chronic lymphocytic leukaemia

Most Recent Events

  • 28 Feb 2016 Will Pharma, MediGene AG and Maastricht University complete a phase II/III trial in Basal cell carcinoma in Netherlands (NCT02029352)
  • 05 Nov 2015 Accelis Pharma agrees to promote polyphenon E in USA for Genital warts
  • 18 Mar 2015 Discontinued - Phase-II for Angina pectoris in Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top